Prana Biotechnology PE Ratio 2006-2021 | ATHE

Current and historical p/e ratio for Prana Biotechnology (ATHE) from 2006 to 2021. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Prana Biotechnology PE ratio as of October 26, 2021 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Prana Biotechnology PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2021-10-27 1.23 inf
2021-06-30 1.30 0 0.00
2020-12-31 1.34 0 0.00
2020-06-30 1.19 0 0.00
2019-12-31 0.78 0 0.00
2019-06-30 1.31 0 0.00
2018-12-31 1.28 0 0.00
2018-06-30 1.89 0 0.00
2017-12-31 3.12 0 0.00
2017-06-30 2.29 0 0.00
2016-12-31 1.63 0 0.00
2016-06-30 4.74 0 0.00
2015-12-31 4.34 0 0.00
2015-06-30 7.02 0 0.00
2014-12-31 9.84 0 0.00
2014-06-30 13.59 0 0.00
2013-12-31 42.06 0 0.00
2013-06-30 13.92 0 0.00
2012-12-31 13.20 0 0.00
2012-06-30 9.42 0 0.00
2011-12-31 8.82 0 0.00
2011-06-30 11.46 0 0.00
2010-12-31 7.50 0 0.00
2010-06-30 6.72 0 0.00
2009-12-31 7.92 0 0.00
2009-06-30 7.20 0 0.00
2008-12-31 11.40 0 0.00
2008-06-30 22.38 0 0.00
2007-12-31 24.00 0 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.029B $0.003B
Prana Biotechnology was established to commercialize research into Alzheimer's disease and other major age-related degenerative disorders. Their mission is to develop diagnostic and therapeutic drugs to treat the central disease pathways that cause degeneration of the brain as the aging process progresses. Prana's technology has emerged from its researchers at prominent international institutions such as Massachusetts General Hospital at Harvard Medical School and the University of Melbourne.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.416B 8.62
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.526B 21.21
Biohaven Pharmaceutical Holding (BHVN) United States $9.249B 0.00
Emergent Biosolutions (EBS) United States $2.705B 6.53
Arcus Biosciences (RCUS) United States $2.404B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.873B 0.00
Myovant Sciences (MYOV) United Kingdom $1.831B 0.00
Zymeworks (ZYME) Canada $1.080B 0.00
Ambrx Biopharma (AMAM) United States $0.464B 0.00
SQZ Biotechnologies (SQZ) United States $0.372B 0.00
Enzo Biochem (ENZ) United States $0.161B 15.86